JFG
ELDN icon

Jefferies Financial Group’s Eledon Pharmaceuticals ELDN Stock Holding History

Jefferies Financial Group’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,094,456
Closed -$3.37M – 1752
2026
Q1 		$3.37M Sell
1,094,456
-486,169
-31% -$1.15M 0.02% 440
2025
Q4 		$2.39M Buy
+1,580,625
New +$3.76M 0.01% 734
2025
Q2 		– Sell
-22,000
Closed -$74.6K – 1444
2025
Q1 		$74.6K Hold
22,000
– – ﹤0.01% 1492
2024
Q4 		$90.6K Buy
+22,000
New +$86.7K ﹤0.01% 1468

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Jefferies Financial Group's ELDN Position: Q2 2026 in Review

Jefferies Financial Group sold out of Eledon Pharmaceuticals (ELDN) in Q2 2026, closing a stake of 1,094,456 shares — an estimated $3.37M sold.

Jefferies Financial Group first reported a position in ELDN in Q4 2024 and held it in 4 quarters. The position peaked at $3.37M in Q1 2026. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Jefferies Financial Group reported no remaining Eledon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 1,094,456 Eledon Pharmaceuticals shares in Q2 2026, an estimated $3.37M.
  • Jefferies Financial Group first reported a position in Eledon Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Jefferies Financial Group's Eledon Pharmaceuticals position peaked at $3.37M in Q1 2026.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.